It should be noted that our findings stand somewhat in contrast to those of Akin and colleagues, who found that while NSC185058 treatment slowed growth in osteosarcoma, it did not appear to alter PI3K or mTOR activity9. The gene discussed is MTOR; the disease is osteosarcoma.